한지연 (국립암센터)님의 논문 목록 | 한빛사논문 > 한빛사

한지연 님의 논문 목록

국립암센터

CV File 102 kb

Proteogenomic characterization identifies clinical subgroups in EGFR and ALK wild-type never-smoker lung adenocarcinoma
- Exp. Mol. Med., 19 September 2024 | https://doi.org/10.1038/s12276-024-01320-0
- 2024-09
- 한빛사논문
Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations
- Cancer Res., APRIL 12 2024 | https://doi.org/10.1158/0008-5472.CAN-23-1551
- 2024-04
- 생명과학
- 한빛사논문
Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer
- J. Exp. Clin. Cancer Res., 2023 Jan 30;42(1):37 | https://doi.org/10.1186/s13046-023-02606-3
- 2023-01
- 생명과학
- 한빛사논문
- 한지연(국립암센터)
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
- Ann. Oncol., Available online 26 November 2021 | https://doi.org/10.1016/j.annonc.2021.11.010
- 2021-11
- 한빛사논문
[LETTER TO EDITOR]Diagnostic and prognostic potential of the oral and gut microbiome for lung adenocarcinoma
- Clin. Transl. Med., First published: 26 September 2021 | https://doi.org/10.1002/ctm2.508
- 2021-09
- 생명과학
- 한빛사논문
- 한지연(국립암센터)
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
- Lancet Oncol., Available online 3 February 2020 | https://doi.org/10.1016/S1470-2045(19)30785-5
- 2020-02
- 한빛사논문
- 한지연(국립암센터)
Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer
- Cancer, Volume 110, Issue 1, pages 138-147, 1 July 2007 | DOI: 10.1002/cncr.22760
- 2007-07
- 상위피인용논문
Comprehensive Analysis of UGT1A Polymorphisms Predictive for Pharmacokinetics and Treatment Outcome in Patients With Non–Small-Cell Lung Cancer Treated With Irinotecan and Cisplatin
- J. Clin. Oncol, May 20, 2006 vol. 24 no. 15 2237-2244. Published online before print April 24, 2006, doi: 10.1200/JCO.2005.03.0239
- 2006-05
- 상위피인용논문
First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
- J. Clin. Oncol., Published online before print February 27, 2012, doi: 10.1200/JCO.2011.36.8456
- 2012-02
- 한빛사논문, 상위피인용논문
Hypoxia-inducible Factor 1α and Antiangiogenic Activity of Farnesyltransferase Inhibitor SCH66336 in Human Aerodigestive Tract Cancer
- JNCI-J. Natl. Cancer Inst., Vol. 97, No. 17, 1272-1286
- 2005-09
- 생명과학
- 한빛사논문

저자논문

저자논문

저자논문

저자논문

CV 열람하기

연락처 보기